Sector News

Edwards Announces Board Change

October 6, 2014
Life sciences
/PRNewswire/ – Edwards Lifesciences Corporation (NYSE: EW), the global leader in the science of heart valves and hemodynamic monitoring, today announced that David E.I. Pyott, a member of the company’s Board of Directors, has submitted his resignation, effective today, in order to devote more time to his role as chairman and chief executive officer of Allergan, Inc.
 
“The board and I are truly appreciative of David’s service and commitment to Edwards during the last 14 years,” said Michael A. Mussallem, Edwards’ chairman and CEO.  “David’s extensive global experience in leadership roles at innovative health and nutrition companies made him a valuable resource for our company.  He has been a trusted partner and brought important expertise to Edwards in delivering novel therapies to address the needs of patients.  We wish him the best and thank him for the significant role he has played in Edwards’ growth and success.”
 
Pyott joined Edwards’ board of directors in 2000, when Edwards was established as an independent, publicly-held corporation.
 
Source: Edwards Lifesciences Corporation

comments closed

Related News

February 4, 2023

MedTrace receives U.S. patent for diagnosing the human heart

Life sciences

The U.S. Patent and Trademark Office issued a patent to MedTrace for their method of diagnosing the human heart via 15O-water PET. The patented method is the foundation of the company’s software aQuant, currently under development. Hendrik “Hans” Harms, PhD and Senior Scientist at MedTrace, and Jens Soerensen, Professor and Clinical Advisor to MedTrace, are the originators of the method.

February 4, 2023

Roche taps insider Teresa Graham for top pharma job as setbacks prompt M&A questions

Life sciences

Teresa Graham, currently head of global product strategy for Roche pharma, will become the division’s new CEO next month, Roche said Thursday. Simultaneously, Roche is elevating Levi Garraway, chief medical officer, to the executive committee.

February 4, 2023

J&J’s pharma group quietly works through global overhaul, with layoffs expected to reach multiple countries

Life sciences

Fierce Pharma has obtained internal documents and video of a town hall meeting conducted this week describing what J&J called a “comprehensive review” of its portfolio. Moving forward, J&J plans to operate its vaccines and infectious diseases outfits as one group, the executives explained.

How can we help you?

We're easy to reach